BCTX
BriaCell Therapeutics Corp.
Price Chart
Latest Quote
$2.80
-0.03 (-1.06%)
Current Price
| Previous Close | $2.83 |
| Open | $2.87 |
| Day High | $2.92 |
| Day Low | $2.74 |
| Volume | 65,695 |
Stock Information
| Shares Outstanding | 8.70M |
| Cash Equivalents | $22.80M |
| Net Income | $-30.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $24.36M |
| EPS (TTM) | $-0.84 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.17M |
| Income | $-30.68M |
| Book/sh | $4.26 |
| Cash/sh | $2.62 |
Financial Ratios
| Quick Ratio | 6.35 |
| Current Ratio | 7.07 |
Returns & Margins
| ROA | -90.84% |
| ROE | -175.25% |
Ownership
| Insider Ownership | 0.51% |
| Institutional Ownership | 5.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.18 |
| P/B | 0.66 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.23 |
| SMA50 | $3.74 |
| SMA200 | $6.76 |
| RSI | 18.55 |
| ATR | 0.2386 |
| Shares Float | 7.86M |
| Short Float | 11.98% |
| Short Ratio | 3.50 |
| Volatility | 1.64 |
| Rel Volume | 0.27 |
Performance History
| Week | -2.78% |
| Month | -16.42% |
| Quarter | -35.03% |
| 6 Months | -68.82% |
| YTD | -60.95% |
| Year | -91.14% |
| 3 Years | -95.26% |
| 5 Years | -95.16% |
| 10 Years | -99.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $2.80 | 66,600 |
| 2026-06-16 | $2.83 | 102,500 |
| 2026-06-15 | $2.74 | 135,300 |
| 2026-06-12 | $2.77 | 192,400 |
| 2026-06-11 | $2.74 | 422,200 |
| 2026-06-10 | $2.88 | 262,100 |
| 2026-06-09 | $3.07 | 301,400 |
| 2026-06-08 | $3.09 | 91,600 |
| 2026-06-05 | $3.08 | 178,300 |
| 2026-06-04 | $3.26 | 102,400 |
| 2026-06-03 | $3.31 | 142,900 |
| 2026-06-02 | $3.27 | 211,800 |
| 2026-06-01 | $3.31 | 744,900 |
| 2026-05-29 | $3.64 | 144,000 |
| 2026-05-28 | $3.58 | 201,500 |
| 2026-05-27 | $3.63 | 216,100 |
| 2026-05-26 | $3.42 | 187,800 |
| 2026-05-22 | $3.49 | 491,900 |
| 2026-05-21 | $3.72 | 197,100 |
| 2026-05-20 | $3.88 | 472,500 |
| 2026-05-19 | $3.51 | 184,800 |
| 2026-05-18 | $3.35 | 366,700 |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
đ° Latest News
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
MT Newswires âĸ 2026-06-01T13:57:47ZBriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies
MT Newswires âĸ 2026-05-14T12:45:41ZBriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study
MT Newswires âĸ 2026-05-06T11:56:21ZTop Midday Decliners
MT Newswires âĸ 2026-01-14T19:10:49ZBig Bank Earnings, Inflation Data in Focus as US Equity Futures Slip Pre-Bell
MT Newswires âĸ 2026-01-14T13:58:52ZTop Midday Gainers
MT Newswires âĸ 2026-01-13T18:54:06ZZacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding
Zacks âĸ 2025-10-28T08:01:00Z
Top 3 Earnings Acceleration Buys for November
Zacks âĸ 2025-10-27T19:05:00Z
BriaCell Adds Three Cancer Centres to Phase 3 Study, Works With MSK Accelerator to Advance Bria-OTS+
MT Newswires âĸ 2025-10-21T12:16:21ZHere's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
Simply Wall St. âĸ 2025-06-25T12:11:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | - | $0 | $0 | $0 |
| Operating Revenue | - | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | - | $33,330,076 | $23,272,264 | $15,285,553 |
| Other Income Expense | - | $28,110,510 | $2,078,657 | $-11,689,102 |
| Net Non Operating Interest Income Expense | - | $288,018 | $891,213 | $135,752 |
| Operating Expense | - | $33,330,076 | $23,272,264 | $15,285,553 |
| General And Administrative Expense | - | $6,152,269 | $7,935,626 | $7,267,452 |
| Interest Expense | - | - | $0 | $979 |
| Interest Expense Non Operating | - | - | $0 | $979 |
| Total Other Finance Cost | - | - | - | $11,658,372 |
| Other Operating Expenses | - | - | - | $-3,388 |
| Rent Expense Supplemental | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | - | $-4,791,466 | $-20,302,394 | $-26,838,903 |
| Net Interest Income | - | $288,018 | $891,213 | $135,752 |
| Interest Income | - | $288,018 | $891,213 | $136,731 |
| Normalized Income | - | $-33,008,486 | $-22,381,051 | $-15,149,801 |
| Net Income From Continuing And Discontinued Operation | - | $-4,791,466 | $-20,302,394 | $-26,838,903 |
| Total Operating Income As Reported | - | $-33,330,076 | $-23,272,264 | $-15,288,941 |
| Net Income Common Stockholders | - | $-4,791,466 | $-20,302,394 | $-26,838,903 |
| Net Income | - | $-4,791,466 | $-20,302,394 | $-26,838,903 |
| Net Income Including Noncontrolling Interests | - | $-4,931,548 | $-20,302,394 | $-26,838,903 |
| Net Income Continuous Operations | - | $-4,931,548 | $-20,302,394 | $-26,838,903 |
| Pretax Income | - | $-4,931,548 | $-20,302,394 | $-26,838,903 |
| Earnings From Equity Interest | - | $-106,510 | $0 | - |
| Interest Income Non Operating | - | $288,018 | $891,213 | $136,731 |
| Operating Income | - | $-33,330,076 | $-23,272,264 | $-15,285,553 |
| Special Income Charges | - | - | - | $0 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Amortization Of Intangibles Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-62.19 | $-43.68 | $-195.00 | $-259.50 |
| Basic EPS | $-62.19 | $-43.68 | $-195.00 | $-259.50 |
| Other | ||||
| Diluted Average Shares | $423,114 | $109,699 | $104,131 | $103,293 |
| Basic Average Shares | $423,114 | $109,699 | $104,131 | $103,293 |
| Tax Effect Of Unusual Items | - | $0 | $0 | $0 |
| Tax Rate For Calcs | - | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | - | $-33,064,671 | $-25,335,650 | $-15,133,550 |
| Total Unusual Items | - | $28,217,020 | $2,078,657 | $-11,689,102 |
| Total Unusual Items Excluding Goodwill | - | $28,217,020 | $2,078,657 | $-11,689,102 |
| Reconciled Depreciation | - | $83,897 | $15,271 | $15,272 |
| EBITDA (Bullshit earnings) | - | $-4,847,651 | $-23,256,993 | $-26,822,652 |
| EBIT | - | $-4,931,548 | $-23,272,264 | $-26,837,924 |
| Diluted NI Availto Com Stockholders | - | $-4,791,466 | $-20,302,394 | $-26,838,903 |
| Minority Interests | - | $140,082 | $0 | - |
| Gain On Sale Of Security | - | $28,217,020 | $2,078,657 | $-11,689,102 |
| Research And Development | - | $27,177,807 | $15,336,638 | $8,021,489 |
| Selling General And Administration | - | $6,152,269 | $7,935,626 | $7,267,452 |
| Other Gand A | - | $6,152,269 | $7,935,626 | $7,267,452 |
| Other Special Charges | - | - | - | - |
| Amortization | - | - | - | - |
| Insurance And Claims | - | - | - | - |
| Rent And Landing Fees | - | - | - | - |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,582,206 | $-3,992,249 | $10,098,593 | $27,426,111 |
| Total Assets | $5,872,261 | $27,163,577 | $42,577,041 | $58,043,762 |
| Total Non Current Assets | $2,218,407 | $215,070 | $230,341 | $245,612 |
| Non Current Prepaid Assets | $1,211,946 | $0 | - | - |
| Goodwill And Other Intangible Assets | $199,796 | $215,068 | $230,339 | $245,610 |
| Other Intangible Assets | $199,796 | $215,068 | $230,339 | $245,610 |
| Current Assets | $3,653,854 | $26,948,507 | $42,346,700 | $57,798,150 |
| Prepaid Assets | $1,422,749 | $4,979,673 | $1,280,945 | $516,891 |
| Receivables | $1,369,016 | $717,742 | $24,103 | $12,574 |
| Other Receivables | $1,369,016 | $717,742 | - | - |
| Cash Cash Equivalents And Short Term Investments | $862,089 | $21,251,092 | $41,041,652 | $57,268,685 |
| Cash And Cash Equivalents | $862,089 | $21,251,092 | $41,041,652 | $57,268,685 |
| Accounts Receivable | - | $18,873 | $24,103 | $12,574 |
| Cash Financial | - | - | - | $57,268,685 |
| Debt | ||||
| Total Debt | - | - | - | $25,986 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $25,986 |
| Long Term Debt | - | - | - | $25,986 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,557,193 | $30,940,758 | $32,248,109 | $30,372,041 |
| Total Non Current Liabilities Net Minority Interest | $1,096,036 | $29,139,301 | $31,307,022 | $29,815,246 |
| Derivative Product Liabilities | $1,096,036 | $29,139,301 | $31,307,022 | $29,789,260 |
| Current Liabilities | $7,461,157 | $1,801,457 | $941,087 | $556,795 |
| Payables And Accrued Expenses | $7,461,157 | $1,801,457 | $941,087 | $556,795 |
| Payables | $7,170,781 | $1,123,739 | $463,280 | $295,083 |
| Accounts Payable | $7,170,781 | $1,123,739 | $463,280 | $214,116 |
| Other Payable | - | - | - | $80,967 |
| Equity | ||||
| Common Stock Equity | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,671,721 |
| Total Equity Gross Minority Interest | $-2,684,932 | $-3,777,181 | $10,328,932 | $27,671,721 |
| Stockholders Equity | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,671,721 |
| Other Equity Interest | $11,033,557 | $7,421,950 | - | $18,371,605 |
| Gains Losses Not Affecting Retained Earnings | $-138,684 | $-138,684 | $-138,684 | $-138,684 |
| Other Equity Adjustments | $-138,684 | $-138,684 | $-138,684 | $-138,684 |
| Retained Earnings | $-85,443,697 | $-80,652,231 | $-60,349,837 | $-29,141,897 |
| Long Term Equity Investment | $418,490 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $121,897 | $106,544 | $103,453 | $101,797 |
| Share Issued | $121,897 | $106,544 | $103,453 | $101,797 |
| Tangible Book Value | $-2,582,206 | $-3,992,249 | $10,098,593 | $27,426,111 |
| Invested Capital | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,697,707 |
| Working Capital | $-3,807,303 | $25,147,050 | $41,405,613 | $57,241,355 |
| Total Capitalization | $-2,382,410 | $-3,777,181 | $10,328,932 | $27,697,707 |
| Minority Interest | $-302,522 | $0 | - | - |
| Capital Stock | $72,166,414 | $69,591,784 | $65,589,293 | $54,774,172 |
| Common Stock | $72,166,414 | $69,591,784 | $65,589,293 | $54,774,172 |
| Current Accrued Expenses | $290,376 | $677,718 | $477,807 | $261,712 |
| Investments And Advances | $418,490 | $2 | $2 | $2 |
| Investmentsin Subsidiariesat Cost | $418,490 | $0 | - | - |
| Net PPE | $388,175 | $0 | - | - |
| Accumulated Depreciation | $-68,626 | $0 | - | - |
| Gross PPE | $456,801 | $0 | - | - |
| Other Properties | $456,801 | - | - | - |
| Additional Paid In Capital | - | $7,421,950 | $5,228,160 | $2,178,130 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,582,929 | $-23,744,860 | $-12,484,376 | $-7,750,188 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,126,128 | $-23,744,860 | $-12,484,376 | $-7,750,188 |
| Cash Flow From Continuing Operating Activities | $-24,126,128 | $-23,744,860 | $-12,484,376 | $-7,750,188 |
| Operating Gains Losses | $-28,135,962 | $-2,119,530 | $11,658,372 | $4,488,864 |
| Investing Activities | ||||
| Capital Expenditure | $-456,801 | - | - | - |
| Investing Cash Flow | $-681,801 | $0 | - | $0 |
| Cash Flow From Continuing Investing Activities | $-681,801 | $0 | - | $0 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-47,294 | $-10,171,732 | $0 |
| Issuance Of Capital Stock | $4,418,926 | $4,000,000 | $0 | $51,622,337 |
| Financing Cash Flow | $4,418,926 | $3,954,300 | $-3,742,657 | $64,997,624 |
| Cash Flow From Continuing Financing Activities | $4,418,926 | $3,954,300 | $-3,742,657 | $64,997,624 |
| Net Common Stock Issuance | $4,418,926 | $3,952,706 | $-10,171,732 | $51,622,337 |
| Common Stock Issuance | $4,418,926 | $4,000,000 | $0 | $51,622,337 |
| Net Other Financing Charges | - | - | $-80,693 | - |
| Other | ||||
| End Cash Position | $862,089 | $21,251,092 | $41,041,652 | $57,268,685 |
| Beginning Cash Position | $21,251,092 | $41,041,652 | $57,268,685 | $21,249 |
| Changes In Cash | $-20,389,003 | $-19,790,560 | $-16,227,033 | $57,247,436 |
| Proceeds From Stock Option Exercised | $0 | $1,594 | $6,509,768 | $13,705,685 |
| Common Stock Payments | $0 | $-47,294 | $-10,171,732 | $0 |
| Net Business Purchase And Sale | $-225,000 | $0 | - | - |
| Purchase Of Business | $-225,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-456,801 | $0 | - | - |
| Purchase Of PPE | $-456,801 | $0 | - | - |
| Change In Working Capital | $7,053,407 | $-3,531,997 | $-391,292 | $-2,282,106 |
| Change In Payables And Accrued Expense | $5,659,703 | $860,370 | $384,292 | $-2,191,063 |
| Change In Accrued Expense | $-387,339 | $199,911 | $135,128 | $-785,399 |
| Change In Payable | $6,047,042 | $660,459 | $249,164 | $-1,405,664 |
| Change In Account Payable | $6,047,042 | $660,459 | $249,164 | $-1,405,664 |
| Change In Prepaid Assets | $2,126,282 | $-4,397,597 | $-764,054 | $-100,984 |
| Change In Receivables | $-732,578 | $5,230 | $-11,530 | $9,941 |
| Stock Based Compensation | $1,804,078 | $2,193,790 | $3,074,584 | $1,968,226 |
| Depreciation Amortization Depletion | $83,897 | $15,271 | $15,272 | $15,256 |
| Depreciation And Amortization | $83,897 | $15,271 | $15,272 | $15,256 |
| Amortization Cash Flow | $15,271 | $15,271 | $15,272 | - |
| Amortization Of Intangibles | $15,271 | $15,271 | $15,272 | - |
| Depreciation | $68,626 | $0 | - | - |
| Earnings Losses From Equity Investments | $106,510 | $0 | - | - |
| Gain Loss On Investment Securities | $-28,242,472 | $-2,119,530 | $11,658,372 | $4,448,957 |
| Net Income From Continuing Operations | $-4,931,548 | $-20,302,394 | $-26,838,903 | $-13,816,200 |
| Repayment Of Debt | - | - | $0 | $-546,108 |
| Issuance Of Debt | - | - | $0 | $215,710 |
| Net Issuance Payments Of Debt | - | - | $0 | $-330,398 |
| Net Short Term Debt Issuance | - | - | $0 | $-330,398 |
| Short Term Debt Payments | - | - | $0 | $-546,108 |
| Short Term Debt Issuance | - | - | $0 | $215,710 |
| Other Non Cash Items | - | - | $-2,409 | $1,875,772 |
| Effect Of Exchange Rate Changes | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $-93,935 |
| Long Term Debt Payments | - | - | - | $-309,645 |
| Long Term Debt Issuance | - | - | - | $215,710 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $0 |
Fetched: 2026-06-16